US FTC seeks more information on Novo Nordisk parent-Catalent deal (updated)

Catalent

03/05/2024 13:36

(Adds details from the filing in paragraphs 3,4)
       May 3 (Reuters) - The U.S. Federal Trade Commission has
sought additional information about a $16.5 billion deal by Novo
Nordisk's  NOVOb.CO  parent to buy manufacturing subcontractor
Catalent  CTLT.N .
    The deal was announced in February and Novo Nordisk
Foundation has since refiled its application to the U.S. FTC
seeking regulatory approval for it.
    Catalent in a regulatory filing on Friday said the companies
were in the process of gathering information and documents to
respond to FTC's request received on May 2 and intend to
continue to cooperate with the regulator.
    Catalent and Novo Holdings expect to close the deal towards
the end of calendar year 2024.
    Novo Holdings is the investment arm of Novo Nordisk's
controlling shareholder, the Novo Nordisk Foundation.
    

 (Reporting by Bhanvi Satija in Bengaluru; Editing by Shilpi
Majumdar)
 ((Bhanvi.Satija@thomsonreuters.com; Outside U.S. +91
9873062788;))